Combined Therapy: Notably, in T2D patients at high risk, combining an SGLT2 inhibitor with a GLP-1 RA yields additive protection for both the heart and kidneys, and the 2022 ADA/EASD consensus now recommends this dual approach for many individuals with cardiorenal disease [198]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.